MX2022011856A - Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos. - Google Patents
Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos.Info
- Publication number
- MX2022011856A MX2022011856A MX2022011856A MX2022011856A MX2022011856A MX 2022011856 A MX2022011856 A MX 2022011856A MX 2022011856 A MX2022011856 A MX 2022011856A MX 2022011856 A MX2022011856 A MX 2022011856A MX 2022011856 A MX2022011856 A MX 2022011856A
- Authority
- MX
- Mexico
- Prior art keywords
- musk
- therapeutic
- antibodies
- present
- musk antibodies
- Prior art date
Links
- 241000402754 Erythranthe moschata Species 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000002232 neuromuscular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a moléculas basadas en anticuerpos, incluyendo anticuerpos de longitud completa, dominios de unión al antígeno de los mismos, y derivados de anticuerpos que son capaces de unirse a, y activar la proteína tirosina cinasa específica de músculo humano (MuSK). La presente invención describe además métodos para tratar condiciones neuromusculares usando los anticuerpos de MuSK mencionados anteriormente.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063011986P | 2020-04-17 | 2020-04-17 | |
US202063038633P | 2020-06-12 | 2020-06-12 | |
US202063112375P | 2020-11-11 | 2020-11-11 | |
PCT/US2021/027801 WO2021212053A2 (en) | 2020-04-17 | 2021-04-16 | Therapeutic musk antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022011856A true MX2022011856A (es) | 2023-02-23 |
Family
ID=75850676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022011856A MX2022011856A (es) | 2020-04-17 | 2021-04-16 | Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11492401B2 (es) |
EP (1) | EP4136115A2 (es) |
JP (1) | JP2023522212A (es) |
KR (1) | KR20230028217A (es) |
CN (1) | CN115843268A (es) |
AU (1) | AU2021256049A1 (es) |
BR (1) | BR112022021065A2 (es) |
CA (1) | CA3175597A1 (es) |
IL (1) | IL297295A (es) |
MX (1) | MX2022011856A (es) |
WO (1) | WO2021212053A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023147489A2 (en) * | 2022-01-28 | 2023-08-03 | argenx BV | Anti-musk antibodies for use in treating neuromuscular disorders |
WO2023218099A1 (en) * | 2022-05-13 | 2023-11-16 | argenx BV | In utero treatment of a fetus having genetic disease/neuromuscular disease |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
US5814478A (en) | 1995-12-15 | 1998-09-29 | Regeneron Pharmaceuticals, Inc. | Tyrosine kinase receptors and ligands |
US6737249B1 (en) | 1997-08-22 | 2004-05-18 | Genentech, Inc. | Agonist antibodies |
US6624819B1 (en) | 2000-05-01 | 2003-09-23 | Broadcom Corporation | Method and system for providing a flexible and efficient processor for use in a graphics processing system |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
JP4166691B2 (ja) | 2001-08-03 | 2008-10-15 | タイコ ヘルスケア グループ エルピー | 組織マーキング装置および方法 |
US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
JP2011207769A (ja) | 2010-03-29 | 2011-10-20 | Arubion:Kk | 化粧料及び皮膚外用剤 |
WO2013074636A1 (en) | 2011-11-14 | 2013-05-23 | New York University | Muscle specific receptor kinase and modulation thereof |
US9574015B2 (en) | 2013-09-13 | 2017-02-21 | New York University | Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK |
-
2021
- 2021-04-16 CA CA3175597A patent/CA3175597A1/en active Pending
- 2021-04-16 IL IL297295A patent/IL297295A/en unknown
- 2021-04-16 EP EP21724109.0A patent/EP4136115A2/en active Pending
- 2021-04-16 MX MX2022011856A patent/MX2022011856A/es unknown
- 2021-04-16 JP JP2022563016A patent/JP2023522212A/ja active Pending
- 2021-04-16 BR BR112022021065A patent/BR112022021065A2/pt unknown
- 2021-04-16 KR KR1020227035693A patent/KR20230028217A/ko active Search and Examination
- 2021-04-16 AU AU2021256049A patent/AU2021256049A1/en active Pending
- 2021-04-16 CN CN202180035285.0A patent/CN115843268A/zh active Pending
- 2021-04-16 WO PCT/US2021/027801 patent/WO2021212053A2/en unknown
- 2021-12-30 US US17/565,994 patent/US11492401B2/en active Active
-
2022
- 2022-10-03 US US17/937,630 patent/US20230151091A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115843268A (zh) | 2023-03-24 |
JP2023522212A (ja) | 2023-05-29 |
WO2021212053A8 (en) | 2022-09-29 |
KR20230028217A (ko) | 2023-02-28 |
BR112022021065A2 (pt) | 2023-02-23 |
US20220259304A1 (en) | 2022-08-18 |
IL297295A (en) | 2022-12-01 |
AU2021256049A1 (en) | 2022-11-03 |
WO2021212053A3 (en) | 2021-11-18 |
EP4136115A2 (en) | 2023-02-22 |
CA3175597A1 (en) | 2021-10-21 |
US11492401B2 (en) | 2022-11-08 |
WO2021212053A2 (en) | 2021-10-21 |
US20230151091A1 (en) | 2023-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021551238A1 (en) | Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof | |
EA201990781A1 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
PH12020552116A1 (en) | Bispecific anti-psma x anti-cd28 antibodies and uses thereof | |
EA202191580A1 (ru) | Биспецифичные антитела анти-cd28 x анти-cd22 и их применение | |
EA202092933A1 (ru) | Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии | |
MX2022011856A (es) | Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos. | |
MX2020008075A (es) | Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos. | |
EA201892548A1 (ru) | Антитела к альфа-синуклеину и их применение | |
BRPI0821658B8 (pt) | anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos | |
EA202091747A1 (ru) | Составы антитела b7-h4 | |
MX2020010913A (es) | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. | |
MX2021008958A (es) | Proteínas de unión a antígeno del receptor gamma anti-il2. | |
MX2022002682A (es) | Anticuerpos anti-cd73. | |
MX2023002940A (es) | Moleculas de union a b7-h4 terapeuticas. | |
EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
MX2022012628A (es) | Anticuerpos anti-phf-tau y usos de estos. | |
MX2022014224A (es) | Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2. | |
MX2023001776A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
MX2022009769A (es) | Anticuerpos anti-acvr1 y usos de los mismos. | |
MX2022004058A (es) | Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo. | |
MX2021015270A (es) | Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb. | |
MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
EA202092122A1 (ru) | Антитела против tip-1 и их применения | |
ZA202110285B (en) | Antibodies and methods of use | |
ZA202205813B (en) | Trpv1 epitopes and antibodies |